Palvella Therapeutics, Inc. Preferred Stock Dividends, Income Statement Impact
Palvella Therapeutics, Inc. (PVLA) reported Preferred Stock Dividends, Income Statement Impact of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2025-11-12
- Palvella Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2024-12-31 was -$582.00K.
- Palvella Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Palvella Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2023 was $776.00K.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | -$582.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | -$582.00K derived: sum of 3 quarters · filed 2025-08-14 | -$388.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | -$582.00K derived: sum of 2 quarters · filed 2025-05-15 | -$388.00K derived: sum of 3 quarters · filed 2025-11-12 | -$194.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-12-31 | -$582.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$388.00K derived: sum of 2 quarters · filed 2025-11-12 | -$194.00K derived: sum of 3 quarters · filed 2025-11-12 | $0.00 10-K · filed 2025-03-31 |
| 2024-09-30 | $194.00K 10-Q · filed 2025-11-12 | $388.00K derived: sum of 2 quarters · filed 2025-11-12 | $582.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $194.00K 10-Q · filed 2025-08-14 | $388.00K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $194.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $776.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |